MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & ...(: Due to limited uniformity in RSV testi...)

surveillance reporting, nationwide RSV prevention programs are not

optimal. A nationwide surveillance program was initiated to track and

report RSV activity at the local level in a timely manner. This

abstract includes an interim report of the data collected to date.

-- Regional Respiratory Syncytial Virus Surveillance Data for Georgia and

Implications for Prophylactic Administration of Palivizumab (Poster

#P32) - Mark Eggleston, PharmD, MBA, Saturday, October 27th, 2007 from

12:15 - 1:00 p.m.

BACKGROUND: The Georgia Division of Public Health initiated an RSV

surveillance program in mid-2000 to monitor RSV activity within four

regions of the state. This study aimed to identify the onset, duration,

and peak month of the RSV season in each of the four regions and

evaluate whether national guidelines for RSV prophylaxis with Synagis

are sufficient or whether recommendations should be based on local RSV

virology data.

Additional information about the 2007 AAP National Conference & Exhibition can be found at http://www.aap.org/nce/.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the ongoing development of motavizumab, Me
'/>"/>